Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com - Bernstein SocGen Group raised its price target on Regeneron Pharma (NASDAQ:REGN) to $753.00 from $750.00 on Monday, maintaining an Outperform rating despite regulatory setbacks. According to InvestingPro data, 10 analysts have recently revised their earnings estimates upward, with price targets ranging from $504 to $940.
The pharmaceutical company reported quarterly revenues of $3.7 billion, exceeding both Bernstein’s and consensus expectations by 13% and 11% respectively, with strong performance across all major products including Eylea and Eylea HD.
Regeneron’s earnings per share reached $12.89, surpassing analyst forecasts by 54%, helped by SG&A spending that came in 18% below expectations.
Despite the strong financial results, Regeneron faces continued regulatory challenges, including an FDA inspection at a former Catalent (NYSE:CTLT) facility (now owned by Novo) that resulted in a second Complete Response Letter for odronextemab.
The regulatory issues are expected to delay pending FDA decisions on several important products, including Eylea HD PFS, Q4W, and RVO, according to Bernstein’s analysis.
In other recent news, Regeneron Pharmaceuticals Inc. reported impressive financial results for the second quarter of 2025, with earnings per share (EPS) reaching $12.89. This figure significantly exceeded analysts’ expectations, which were set at $8.50, marking a 51.65% outperformance. Additionally, Regeneron’s revenue for the quarter totaled $3.68 billion, surpassing the anticipated $3.29 billion. These results indicate a strong performance for the company, contributing to investor confidence. No mergers or acquisitions were reported in this period. Analyst firms have not issued any upgrades or downgrades in relation to these earnings results. The company’s robust financial performance stands out as a key development in recent news.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.